Simoens Steven, De Coster Sandra, Lenie Jan, Hayen Véronique, Laekeman Gert
Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven ( Belgium ).
Royal Pharmaceutical Society of Limburg, Hasselt (Belgium).
Pharm Pract (Granada). 2011 Apr;9(2):88-92. doi: 10.4321/s1886-36552011000200005. Epub 2011 Jun 17.
This study aims to use a pharmacoepidemiological approach to study the drug use of patients during the year prior to diabetes diagnosis (i.e. pre-diabetic patients) and control patients. Drug use might reveal cardiovascular, metabolic and/or endocrinological changes and help to identify indicators for active monitoring of Type 2 diabetes mellitus.
A retrospective case-control study compared drug use of patients with a future diagnosis of diabetes (experimental patients) with patients without a diabetes diagnosis (control patients) based on community pharmacy records. An experimental patient had used oral hypoglycaemic drugs during 2005 or 2006. Experimental and control patients were matched in terms of age, gender and quarter of index date. Drugs were selected based on possible co-morbidities of diabetes. Drug use was expressed as a binary variable, indicating whether or not a patient took specific drugs. Drug use was compared between experimental patients during the year prior to diagnosis and control patients using the chi-squared test.
Our dataset covered 5,064 patients (1,688 experimental and 3,376 control patients). A higher probability of taking cardiovascular drugs was observed for specific subgroups of patients with pre-diabetes as compared to control patients: this trend was observed for men as well as for women, for various cardiovascular drug classes, and for different age groups (p<0.05), although it was not always statistically significant for the 29-38 age group. For each selected age and gender group, patients with pre-diabetes had a higher probability of taking a combination of a lipid-modifying agent and an antihypertensive drug than control patients (p<0.005).
Using community pharmacy data, this study demonstrated that age and a characteristic drug use pattern could contribute to detecting pre-diabetes. There is a potential role for community pharmacists to follow up drug indicators of patients with a view to refer high-risk people for screening by a physician.
本研究旨在采用药物流行病学方法,研究糖尿病诊断前一年患者(即糖尿病前期患者)和对照患者的用药情况。药物使用情况可能揭示心血管、代谢和/或内分泌变化,并有助于识别积极监测2型糖尿病的指标。
一项回顾性病例对照研究,根据社区药房记录,比较未来诊断为糖尿病的患者(试验患者)和未诊断为糖尿病的患者(对照患者)的用药情况。试验患者在2005年或2006年使用过口服降糖药。试验患者和对照患者在年龄、性别和索引日期季度方面进行匹配。根据糖尿病可能的合并症选择药物。药物使用情况用二元变量表示,表明患者是否服用特定药物。使用卡方检验比较诊断前一年试验患者和对照患者的药物使用情况。
我们的数据集涵盖5064名患者(1688名试验患者和3376名对照患者)。与对照患者相比,糖尿病前期特定亚组患者服用心血管药物的可能性更高:男性和女性、各种心血管药物类别以及不同年龄组均观察到这种趋势(p<0.05),尽管在29-38岁年龄组中并非总是具有统计学意义。对于每个选定的年龄和性别组,糖尿病前期患者服用降脂药和抗高血压药组合的可能性高于对照患者(p<0.005)。
本研究利用社区药房数据表明,年龄和特定的用药模式可能有助于检测糖尿病前期。社区药剂师有可能跟踪患者的药物指标,以便将高危人群转介给医生进行筛查。